Tag: Phase 2a
-
Can Sionna Challenge Vertex’s Cystic Fibrosis Empire?
Sionna’s NBD1-stabilizing therapy could become the first credible challenge to Vertex’s dominant cystic fibrosis franchise.
Sionna’s NBD1-stabilizing therapy could become the first credible challenge to Vertex’s dominant cystic fibrosis franchise.